Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 5 of the 18 sources its claims cite were checked for support.

Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans

Open access

Abstract

Serotonin is implicated in multiple executive functions including goal-directed learning, cognitive flexibility, response inhibition and emotional regulation. These functions are impaired in several psychiatric disorders, such as depression and obsessive-compulsive disorder. We tested the cognitive effects of the selective serotonin reuptake inhibitor escitalopram, using an acute and clinically relevant dose (20 mg), in 66 healthy male and female volunteers in a double-blind, placebo-controlled study. Participants performed a cognitive test battery including a probabilistic and reversal learning task, the CANTAB intra-dimensional/extra-dimensional shift test of cognitive flexibility, a response inhibition task with interleaved stop-signal and No-Go trials and tasks measuring emotional processing. We showed that acute escitalopram administration impaired learning and cognitive flexibility, but improved the ability to inhibit responses in stop-signal trials while leaving unaffected acute emotional processing. Our findings suggest a dissociation of effects of acute escitalopram on cognitive functions, possibly mediated by differential modulation of brain serotonin levels in distinct functional neural circuits.

Overview

CoChat Summary

TL;DR

Acute escitalopram (20 mg) in healthy volunteers produced dissociable cognitive effects: it impaired probabilistic learning and cognitive flexibility but improved stop-signal response inhibition, while leaving emotional processing largely unaffected. The authors interpret this as evidence that acute SSRI effects on cognition are not uniform and may reflect differential modulation of serotonin in distinct neural circuits.

Key findings

  • Acute escitalopram impaired probabilistic learning: the escitalopram group made significantly more Stage 1 errors than placebo (U = 314, z = −2.850, p = 0.004), with lower win-stay probability (p = 0.043) and higher lose-shift probability (p = 0.013); lose-shift after misleading feedback was higher in the escitalopram group (p = 0.003, F(1,62) = 9.724, partial η² = 0.136). Stage 2 reversal errors and RTs did not differ (p > 0.05).
  • Acute escitalopram impaired cognitive flexibility on the CANTAB ID/ED task: there was a significant stage-by-treatment effect (p = 0.026, F(3,52) = 3.339, partial η² = 0.162), and the escitalopram group made more EDS errors (mean 11.4, SD 10.49) than placebo (mean 5.43, SD 6.93), p = 0.014, F(1,56) = 6.449, partial η² = 0.103; EDS responding was also slower (p = 0.026).
  • Acute escitalopram improved response inhibition: it significantly reduced stop-signal reaction time (SSRT), p = 0.013, t(62) = −2.550, without significant changes in other response-inhibition measures.
  • Emotional processing was largely unaffected: acute escitalopram did not alter affective bias in the three emotional tasks, but increased the proportion of facts chosen in the EMOTICOM social information preference task (p = 0.017, t = 2.451, partial η² = 0.095).

Methods

  • Double-blind, placebo-controlled, parallel-groups study in healthy volunteers; participants received acute escitalopram 20 mg (equivalent to 40 mg racemic citalopram) or placebo, with neuropsychological testing starting 3 h after pill administration. Overall, 65 healthy volunteers completed testing (placebo N = 33, escitalopram N = 32); groups were matched demographically and on baseline mood.
  • Cognitive battery included a probabilistic reversal learning task, the CANTAB intra-dimensional/extra-dimensional set shift task, an integrated Stop-signal/No-Go response inhibition task, and emotional processing tasks (EMOTICOM face affective Go/No-Go, CANTAB affective Go/No-Go, EMOTICOM social information preference). Mood state and personality questionnaires included BDI and STAI.
  • Analyses used SPSS v23 with chi-square tests, two-tailed t tests, and ANOVAs; Benjamini–Hochberg false discovery rate control was applied across all hypotheses at q < 0.15, giving a corrected significance level of 0.018.

Limitations

  • The paper states that only one dose of escitalopram was used, although it was the clinically highest allowed dose and higher acute doses were precluded by ethical considerations; a sub-chronic study was said to be urgently indicated to determine whether acute effects persist or reverse.
  • The paper states that a between-group design was used because of practice effects confounding crossover designs, though groups were well matched; many cognitive and emotional tests were administered, but false discovery rate was controlled across the battery.
  • The text makes evident that sample sizes varied across task analyses due to exclusions/outliers, and the authors note that behavioural measures of emotional processing were somewhat insensitive to acute SSRI treatment; they also note that the dose produced plasma levels comparable with the lower end of the clinical range, and direct comparison with prior studies was not possible because plasma levels were not routinely reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41386-018-0229-z

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Escitalopram group made significantly more errors in the EDS, compared with the placebo group, following false discovery rate control of q < 0.15 with the Benjamini–Hochberg procedure, as denoted with an asterisk
Fig. 1 Escitalopram group made significantly more errors in the EDS, compared with the placebo group, following false discovery rate control of q < 0.15 with the Benjamini–Hochberg procedure, as denoted with an asteriskCC BY · PubMed Central

Verification

Claims the paper makes

5 Valid · 0 Not valid · 10 Not checked · 42 Own results and interpretations

28 more claims

Create a free account to see all 57 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 11

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Statistics recomputed

Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.

  • Consistentz = -2.85reported p = .004 · recomputed p = .004

    “z = −2.850, p = .004”

1 of 1

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 59 references

Research works printed but not linked: 1

  1. Sheehan DV, Janavs J, Baker R, Harnett-Sheehan K, Knapp E, Sheehan M, et al. MINI-mini international neuropsychiatric interview-english version 5.0. 0-DSM-IV. J Clin Psychiatry. 1998;59:34–57.

Cited by

See all 97

Metadata

Authors
Skandali, N., Rowe, J. B., Voon, V., Deakin, J. B., Cardinal, R. N., Cormack, F., Passamonti, L., Bevan-Jones, W. R., Regenthal, R., Chamberlain, S. R., Robbins, T. W., & Sahakian, B. J.
Affiliations
  • University of Cambridge (GB)
  • Cambridge Cognition (United Kingdom) (GB)
  • Leipzig University (DE)
Corresponding author
Skandali, Nikolina
Venue
Neuropsychopharmacology
Published
2018-09-26
Volume
43
Issue
13
Pages
2645-2651
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2892955830
Cited by
89
References
59
Citations by year
2026: 5 · 2025: 7 · 2024: 8 · 2023: 20 · 2022: 10 · 2021: 18 · 2020: 17 · 2019: 4
FWCI
4.44
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Neuropsychopharmacology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • James S. McDonnell Foundation
  • Eli Lilly and Company
  • Wellcome Trust (103838/Z/14/Z, 103838, MR/P008747/1, 110,049/Z/15/Z, 104631/Z/14/Z, /Z/15/Z, 110049, 104631)
  • National Institute for Health and Care Research (MR/P008747/1, 103838)
  • Shionogi
  • Bundesministerium für Wirtschaft und Energie
  • H. Lundbeck A/S
  • Medical Research Council (MR/P01271X/1, MC_PC_17213, MR/M024873/1, MR/P008747/1, MR/M009041/1)
  • NIHR Cambridge Biomedical Research Centre (MR/P008747/1)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
escitalopram, selective serotonin reuptake inhibitors, acute drug effects, executive function, cognitive flexibility, reversal learning, probabilistic learning, response inhibition, stop-signal task, emotional processing, serotonin, cognitive impairment
MeSH terms
Adult, Cognition, Dissociative Disorders, Double-Blind Method, Emotions, Female, Humans, Male, Reversal Learning, Citalopram, Selective Serotonin Reuptake Inhibitors, Young Adult, Executive Function

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans. https://app.cochat.ai/papers/10.1038/s41386-018-0229-z
The paper
Skandali, N., Rowe, J. B., Voon, V., Deakin, J. B., Cardinal, R. N., Cormack, F., Passamonti, L., Bevan-Jones, W. R., Regenthal, R., Chamberlain, S. R., Robbins, T. W., & Sahakian, B. J. (2018). Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans. Neuropsychopharmacology. https://doi.org/10.1038/s41386-018-0229-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.